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Although the prognostic signiﬁcance of vascular endothelial growth factor (VEGF) has been researched
extensively in patients with hematologic malignancies undergoing chemotherapy, its role in allogeneic
hematopoietic stem cell transplantation (HSCT) requires further investigation. The present study evaluated
the associations between VEGF level and relapse rate and early complications after HSCT. VEGF levels were
analyzed in 91 consecutive patients before the start of conditioning, on day 0, on the day of engraftment, and
on the day of diagnosis of veno-occlusive disease (VOD). Compared with a normal level, an elevated high
VEGF-A level before conditioning was associated with an increased 2-year relapse rate (55% versus 24%,
P ¼ .003; hazard ratio [HR], 3.25; 95% conﬁdence interval [CI], 1.49 to 7.08) and decreased event-free survival
(20% versus 44%; P ¼ .022; HR, 2.03; 95% CI, 1.11 to 3.72). No association was found between VEGF level and
the incidence of acute GVHD (P > .05). In patients with VOD, VEGF-A level was elevated on day 0 and on the
day of VOD diagnosis (P < .05). A low VEGF-A level on day 0 was associated with reduced nonrelapse
mortality (14% versus 35%; P ¼ .048; HR, 0.32; 95% CI, 0.10 to 0.99). Our results indicate that a high VEGF-A
level before HSCT increases the risk of relapse, and a high level after conditioning is associated with increased
risks of early complications and nonrelapse mortality.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION dysfunction in the complications of HSCT [15,16], few studies
Vascular endothelial growth factor (VEGF) is cytokine
involved in angiogenesis [1]. The human VEGF gene family
comprises 5 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D,
and placental growth factor [2]. Considered one of the most
potent angiogenic molecules, VEGF-A is involved in neo-
vascularization in situations of reparation as well as tumor
growth. Its signiﬁcance in solid tumor growth is well estab-
lished [3].
Recent studies have emphasized the role of VEGF-A in the
progression of hematologic malignancies, with VEGF-A over-
expression associated with altered morphology of bone
marrow and increased vascularization of bone marrow in
myeloproliferative disorders [4,5]. Elevated VEGF-A levels
are also associated with worse chemotherapy outcomes in
patients with acute myelogenous leukemia [6], chronic mye-
logenous leukemia [7], acute lymphoblastic leukemia [8],
myelodysplastic syndrome [9], and various types of lympho-
proliferation [10-12]. The signiﬁcance of this negative prog-
nostic factor in recipients of allogeneic hematopoietic stemcell
transplantation (HSCT) has not yet been established, however.
Apart from tumor-associated expression, VEGF-A
expression is up-regulated in the presence of endothelial
damage and has been extensively studied as an endothelial
damage marker in cardiovascular disorders [13,14]. Although
there is increasing interest in the role of endothelialdgments on page 1681.
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13.08.015to date have focused on VEGF-A. Several reports have sug-
gested that VEGF-A may play a role in the development of
acute graft-versus-host disease (GVHD) and that VEGF-A
level is correlated with transplantation-related mortality
[17-19]. The signiﬁcance of VEGF-A in endothelial injury
syndromes has not been evaluated in humans, but in animal
models elevated levels were associated with increased
vascular permeability and capillary leak, and thus may play
a role in the pathogenesis of severe veno-occlusive disease
(VOD) [20,21].
The primary goal of the present study was to test whether
an elevated VEGF-A level before HSCT is associated with
worse disease prognosis after allografting. A second goal was
to investigate relationships among VEGF-A level, nonrelapse
mortality (NRM), andmajor complications of HSCT, including
acute GVHD and VOD.PATIENTS AND METHODS
Patients
This study was based on the analysis of plasma samples and hospital
records of 91 consecutive adult patients with a hematologic malignancy
undergoing HSCT in R.M. Gorbacheva Memorial Institute of Children
Hematology and Transplantation. Samples for the study were collected
prospectively between 2010 and 2012. The study was approved by the
Ethical Committee of I.P. Pavlov State Medical University, and informed
consent was received from all patients for blood collection.
The distribution of disorders was 73% acute leukemia, 10% chronic
myelogenous leukemia, 8% myelodysplastic syndrome, and 9% other
hematologic malignancies. Median age was 38 years (range, 18 to 60 years),
and median performance score and modiﬁed European Group for Blood and
Marrow Transplantation risk score [22,23] were 1 (range, 0 to 3) and 4
(range, 1 to 6) respectively. The graft donor was related in 30% and unrelated
in 70%. Pretransplantation conditioning was myeloablative in 24% andTransplantation.
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oral busulfan and 120 mg/kg cyclophosphamide. Reduced-intensity condi-
tioning was based on 180 mg/m2 ﬂudarabine and 8 mg/kg busulfan or
140 mg/m2 melphalan in cases involving previous busulfan-based condi-
tioning or anamnesis of neurologic disorders. Acute GVHD prophylaxis
consisted of calcineurin inhibitor (tacrolimus in 81% of patients) and short-
course methotrexate. Antilymphocyte globulin (Atgam; Pﬁzer, New York,
NY) 60 mg/kg was used in unrelated transplants. All but 2 patients received
a single allogeneic graft. Ten patients had undergone previous autologous
HSCT. Detailed patient characteristics are given in Table 1. VOD prophylaxis
with ﬁxed-dose heparin was performed in all patients.
The staging and grading of acute GVHD were done using the modiﬁed
Glucksberg consensus criteria [24] at the initiation of treatment. VOD was
diagnosed clinically according to the modiﬁed Seattle criteria extended up
to day þ30 after HSCT, which required the presence of at least 2 of the
following 3 clinical ﬁndings: jaundice with bilirubin >34 mmol/L, painful
hepatomegaly, and ﬂuid retention >5% of body weight. VOD was classiﬁed
as severe in the presence of multiorgan failure.
Laboratory Methods
Venous blood was collected using EDTA anticoagulant from the central
venous catheter before the start of conditioning, on the day of HSCT (day 0)
before graft transfusion, on the day of engraftment, and on the day of VOD
diagnosis. Blood samples were centrifuged for 15 minutes at 1000  g, and
aliquot plasma was stored in polypropylene tubes at 80C until the day of
the assay.
VEGF-A concentrations in plasma samples were measured by ELISA
using a commercially available kit (eBioscience, San Diego, CA) according to
the manufacturer’s instructions. The detection limit was 7.9 to 1000 pg/mL.
Concentrations were determined without knowledge of clinical data.
Statistical Analysis
Data analysis was performed with SPSS version 17.0 (SPSS Inc, Chicago,
IL). The chi-squared test and t test were used for univariate nonparametric
and parametric analysis, respectively. VEGF levels in patients with VODwere
analyzed using the Mann-Whitney U test. The diagnostic signiﬁcance ofTable 1
Patient and Transplantation Characteristics
Characteristic Value
Number of patients 91
Males, n (%) 46 (50.5)
Females, n (%) 45 (49.5)
Age, y, median (range) 38 (15-60)
Performance status score, median (range) 1 (0-3)
Modiﬁed European Group for Blood and Marrow
Transplantation risk score, median (range)
4 (1-6)
Diagnosis, n (%)
Acute myelogenous leukemia 51 (56.0)
Acute lymphoblastic leukemia 15 (16.5)
Chronic myelogenous leukemia 9 (9.9)
Myelodysplastic syndrome 7 (7.7)
Multiple myeloma 3 (3.3)
Idiopathic myeloﬁbrosis 3 (3.3)
Other malignancies 3 (3.3)
Disease status before HSCT, n (%)
Remission 43 (47.3)
No remission 48 (52.7)
Previous autologous or allogeneic HSCT, n (%) 12 (13.2)
Cytogenetic risk, n (%)
Low 1 (1.1)
Intermediate 38 (41.8)
High 27 (29.7)
Donor characteristics, n (%)
Related 27 (29.7)
Unrelated 64 (70.3)
HLA-matched 10/10 76 (83.5)
Single HLA mismatch 9/10 15 (16.5)
Conditioning regimen, n (%)
Myeloablative 22 (24.2)
Reduced-intensity 69 (75.8)
Transplant source, n (%)
Bone marrow 26 (28.6)
Mobilized peripheral blood stem cells 62 (68.1)
Both 3 (3.3)
CD34þ cell dose,  106/kg, mean  SD 5.2  2.0VEGF in VOD was evaluated by receiver operating characteristic (ROC) curve
analysis. The Kruskal-Wallis test was used to determine the effect of pre-
transplantation therapy on VEGF level before conditioning. Kaplan-Meier
survival analysis and the log-rank test [25,26] were used for univariate
survival, transplantation-related mortality, and cumulative incidence of
relapse comparisons. Multivariate analysis was performed using Cox
regression [27]. Multivariate models were constructed using stepwise
forward selection, using a P value .01 (Bonferroni correction) to include
variables in the model. The proportional-hazards assumptionwas tested for
each variable individually; all variables met this assumption. VEGF cutoff
levels for survival analysis were determined based on ROC curves. VEGF
measurements at various time points were selected for KaplaneMeier
analysis and Cox regression if the ROC area under the curve (AUC) for that
time point was 0.6.
Clinical data collection continued until dayþ100 after HSCT, after which
patients were followed up for survival and relapse. The median duration of
follow-up was 406 days (range, 135 to 730 days). NRM was deﬁned as the
cumulative incidence of death from the date of HSCT not related to the
relapse and its subsequent treatment. Event-free survival (EFS) was deﬁned
as the time from the date of HSCT to the documented event (relapse or
death).
RESULTS
We analyzed VEGF concentrations in 91 consecutive
patients undergoing HSCT. Engraftment was achieved in 90%
of patients, and the other 10% had primary graft failure or
progressive disease. In the entire study group, 2-year overall
survival (OS) was 51%, 2-year EFS was 38.5%, 2-year NRMwas
30.8%, and the 2-year cumulative incidence of relapse was
31%. VOD was diagnosed in 13 patients (14%), with severe
VOD in 10%. The median time to VOD diagnosis was 13 days
(range, 6 to 21 days) after HSCT, and the median interval
between VOD diagnosis and engraftment was 5 days. Acute
GVHD grade I-IV was diagnosed in 54.4% of the patients;
grade III-IV, in 20.9%.
VEGF-A Concentrations
The mean VEGF-A concentration was 177  799 pg/mL
before conditioning, 147  660 pg/mL on day 0, and
171  781 pg/mL on engraftment. Concentrations were
below the level of quantiﬁcation (<7.8 pg/mL) in 24.2%
before conditioning, in 31.9% on day 0, and in 27.5% on
engraftment. The widely variable results can be attributed
mainly to 6 patients (3 with chronic myelogenous leukemia,
1 with acute lymphoblastic leukemia, 1 with acute myelog-
enous leukemia, and 1 with acute plasmoblastic leukemia)
with concentrations above the upper limit of quantiﬁcation
at 2 or 3 of the 3 time points and with samples tested in
dilution. All 6 of these patients had either no hematologic
remission or measurable minimal residual disease at the
time of HSCT, and thus the high concentrations in these
patients were attributed to tumor-associated production.
VEGF-A Level and Relapse Rate
Patients who underwent HSCT without hematologic
remission had higher preconditioning and day 0 VEGF-A
levels compared with those undergoing HSCT while in
remission (349  1158 versus 29  57 pg/mL [P ¼ .11] and
263 926 versus 68 377 [P¼ .004], respectively), although
the difference at the preconditioning time point was not
statistically signiﬁcant. Only VEGF level before the start of
conditioning had the required statistical power to predict
relapse. The AUC values for VEGF conditioning were 0.61
before conditioning, 0.51 on day 0, and 0.49 on engraftment.
For subsequent relapse and survival analysis, patients were
divided into 2 groups according to the predetermined VEGF
cutoff level of 37 pg/mL. Patients with a VEGF-A concentra-
tion>37 pg/mL had an elevated cumulative relapse rate (55%
Figure 1. Two-year cumulative incidence of relapse (A) and 2-year EFS (B) according to VEGF-A level before conditioning.
Table 2
Univariate and Multivariate Analysis of Factors Effecting Cumulative Relapse
Rate, NRM, and EFS
Factor Univariate
P Value
Multivariate
P Value
HR (95% CI)
Cumulative relapse rate
Unrelated versus related
donor
.007 .039 0.46 (0.21-0.96)
Active disease at the
time of HSCT
.094
Myeloablative versus
reduced-intensity
conditioning
.156
Acute GVHD grade I-IV .026 .046 0.44 (0.20-0.99)
Chronic GVHD .021 .070
VEGF-A >37 pg/mL
before conditioning
.002 .003 3.25 (1.49-7.08)
NRM
Active disease at the
time of HSCT
<.001 .001 4.63 (1.83-11.69)
Age .044 .019 0.96 (0.93-0.99)
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EFS (20% versus 44%; P ¼ .023) compared with those with
a level below the cutoff (Figure 1). Surprisingly, OS did not
differ signiﬁcantly in the 2 groups (61% versus 49%; P¼ .334),
because the majority of patients in the high VEGF group
responded to salvage therapy after relapse. In multivariate
analysis, VEGF-A concentration>37 pg/mL before the start of
conditioning remained a signiﬁcant independent risk factor
for relapse (HR, 3.33; 95% CI, 1.15 to 7.32; P ¼ .003) and
decreased EFS (HR, 2.03; 95% CI, 1.11 to 3.72; P ¼ .022)
(Table 2).
Similar results were observed for the less-heterogenous
group of acute leukemia patients with a pretransplantation
VEGF-A level >37 pg/mL. Owing to the small number of
patients, we found only a statistical trend toward an
increased relapse rate (46% versus 25%; P¼ .07), although the
difference in EFS remained signiﬁcant (23% versus 51%;
P ¼ .039).
We performed an additional analysis to exclude the effect
of pretransplantation chemotherapy on VEGF-A level before
conditioning. Time from diagnosis to HSCT (P ¼ .83), number
of previous courses of chemotherapy (P ¼ .12), number of
courses of high-dose chemotherapy (P ¼ .82), previous HSCT
(P ¼ .11), and time from the last course of chemotherapy
(P ¼ .28) had no signiﬁcant effect on VEGF-A level.Previous HSCT .002 .029 3.18 (1.29-8.96)
Unrelated versus related
donor
.20
Myeloablative versus
reduced-intensity
conditioning
.43
Acute GVHD grade III-IV <.001 .006 3.96 (1.48-10.58)
VOD <.001 .024 3.33 (1.69-9.47)
VEGF-A <7.8 pg/mL on
day 0
.046 .048 0.32 (0.10-0.99)
EFS
Active disease at the
time of HSCT
<.001 <.001 3.70 (1.87-7.35)
Age .13
Previous HSCT <.001 .004 3.06 (1.44-6.49)
Unrelated versus related
donor
.28
Myeloablative versus
reduced-intensity
conditioning
.44
Acute GVHD grade I-IV .018 .051
Chronic GVHD <.001 <.001 0.26 (0.13-0.54)
VOD <.001 .007 2.9 (1.34-6.28)
VEGF-A >37 pg/mL
before conditioning
.023 .022 2.03 (1.11-3.72)
VEGF-A <7.8 pg/mL on
day 0
.55
HR >1 indicates increased risk of relapse and NRM, and decreased EFS.VEGF-A Level and Early Complications of HSCT
We found no statistically signiﬁcant differences in VEGF
levels before conditioning, on day 0, and on engraftment
between patients with and those without acute GVHD grade
I-IV and grade III-IV (P > .05). This study had an additional
focus on VOD, considering that this complication of HSCT is
known to be associated with signiﬁcant endothelial damage
and there was an additional blood collection time point on
the day of VOD diagnosis. Because VOD was diagnosed on
different days after HSCT between day 0 and engraftment,
these latter 2 time points were used for comparison in the
non-VOD group. VEGF levels before conditioning and on
engraftment were not signiﬁcantly different in the 2 groups
(42  64 pg/mL versus 53  154 pg/mL [P ¼ .719] and
26 28 pg/mL versus 23 35 pg/mL; P¼ .718], respectively).
However, in the VOD group, higher VEGF-A levels were
observed on day 0 (52  55 pg/mL versus 33  120 pg/mL;
P ¼ .045) and on the day of VOD diagnosis compared with
those seen in the non-VOD group on day 0 (128  147 pg/mL
versus 33 120 pg/mL; P ¼ .003) and the day of engraftment
(128 147 pg/mL versus 23 35 pg/mL; P ¼ .008) (Figure 2).To evaluate the predictive signiﬁcance of day 0 VEGF level
on the incidence of VOD, we divided the patients into 2
groups based on a VEGF-A cutoff level of<7.8 pg/mL that was
subsequently found to be highly speciﬁc for overall NRM.
Patients in the low-VEGF group demonstrated only a trend
toward reduced risk of VOD (7% versus 25%; P ¼ .126), but
Figure 2. Level of VEGF-A in patients with and without VOD.
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(0% versus 19%; P ¼ .024). Despite signiﬁcant elevated VEGF
levels in the patients with VOD, the utility of VEGF-A as
prognostic marker (AUC ¼ 0.74) or a diagnostic marker
(AUC ¼ 0.55) of VOD was relatively low, with sensitivity of
67% and 62% and speciﬁcity of 79% and 58%, respectively.VEGF-A Level and NRM
Only VEGF-A level on day 0 was predictive for NRM
(AUC ¼ 0.67), whereas levels before conditioning
(AUC ¼ 0.46) and on engraftment (AUC ¼ 0.57) lacked
sufﬁcient predictive power. The VEGF cutoff level on day
0 with the greatest sensitivity and speciﬁcity for NRM was
below the limit of quantiﬁcation of 7.8 pg/mL. Patients with
a VEGF-A level <7.8 pg/mL had a signiﬁcantly lower NRM on
day 0 (14% versus 35%; P ¼ .046) (Figure 3). In a multivariate
analysis of factors predicting NRM, VEGF-A level below the
limit of quantiﬁcation was an independent factor associatedFigure 3. Two-year NRM according to VEGF-A level on the day of HSCT.with reduced mortality (HR, 0.32; 95% CI, 0.10 to 0.99;
P ¼ .048) (Table 2). Our analysis of underlying causes of NRM
in the low-VEGF and high-VEGF groups could not determine
the reason for the observed differences in mortality.
Mortality from infectious complications (P ¼ .77), acute
GVHD (P ¼ .94), graft failure (P ¼ .39), and vascular compli-
cations, including VOD (P ¼ .79), differed in the 2 groups on
day 0.DISCUSSION
This study of VEGF-A measured at different time points
surrounding HSCT demonstrates the dual role of VEGF-A. Its
overexpression before conditioning was associated with
increased risk of relapse andmight represent amechanism of
tumor resistance, given that none of the pretransplantation
factors were found to affect VEGF-A levels. On the other
hand, the observed association between VEGF-A level after
conditioning and NRM and VOD conﬁrms VEGF-A’s signiﬁ-
cance as an endothelial damage marker in the setting of
HSCT.
Tumor-associated production of VEGF-A as a possible
mechanism of resistance to chemotherapy has been studied
extensively in various hematologic neoplasms [6-12], but to
the best of our knowledge, this is the ﬁrst study to conﬁrm the
negative prognostic effect of a high VEGF-A level before
conditioning onHSCToutcomes. Another importantﬁndingof
this research is that despite an increased rate of early relapse,
there were no differences in overall survival in high VEGF and
low VEGF groups of patients. Although the follow-up was
relatively short, and longer observational periods might have
revealed differences, successful post-transplantation salvage
chemotherapyanddonor lymphocyte infusion inat least some
patients in the higheVEGF-A group demonstrates the poten-
tial utility of the graft-versus-leukemia effect to overcome this
factor in resistance. Allogeneic HSCT is considered a treatment
of choice for high-risk disease in patients with acute leuke-
mias, myelodysplastic syndrome, chronic myelogenous
leukemia, and lymphomas [28-31]. Given that standard
therapy outcomes for these malignancies have been reported
to be negatively inﬂuenced by VEGF-A overexpression, more
studies are needed to determine whether patients with high
VEGF-A levels should be candidates for HSCT.
Interpreting the data on VEGF-A as an endothelial
damage marker requires an understanding of the mecha-
nisms and factors regulating its level in plasma. VEGF-A is
secreted by a wide variety of cells, including endothelial and
blood mononuclear cells. It is eliminated via cleavage with
serum proteases and binding to either soluble or cellular
VEGF receptors. However, a large proportion of VEGF is
bound to extracellular matrix (ECM) heparin sulfate
proteoglycans. In response to endothelial and tissue damage,
ECM-bound VEGF is cleaved from proteoglycan complexes
and released into circulation to facilitate reparation. The
important factor is that serum protease activity in terms of
VEGF elimination is insufﬁcient to decrease levels in situa-
tions of extensive release from ECM [32-34], resulting in
elevated levels of circulating VEGF in cases of substantial
endothelial damage, such as a conditioning regimen. Another
important factor is that VEGF-A is bound to heparin. Several
studies have indicated that administration of heparin results
in decreased serum VEGF levels, which may be falsely
interpreted [35,36]. In the present study, all patients received
a ﬁxed-dose continuous infusion of heparin and all blood
collections were done at the steady-state level, and thus
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VEGF concentrations related to this factor.
Observed differences inNRMaccording toVEGF-A level on
day 0 conﬁrm the signiﬁcance of endothelial damage by
conditioning on the outcome of HSCT. Levels of another
molecule involved in angiogenesis, angiopoietin-2, have been
correlated with NRM as well [37,38]. In this study, the
statistical analysis of VEGF levels allowed to distinguish only
patients with low risk of NRM. This could be explained by
possible residual tumor-associated secretion on day 0 in
patients with VEGF-Aeexpressing neoplasms, which inter-
fered in the analysis and did not allow to distinguish the high-
risk group for NRM, but we were not able to conﬁrm this
hypothesis in our research. In addition, owing to our limited
number of patients, we could not analyze the differences in
the major causes of NRM, including infectious complications,
acute GVHD, graft failure, and vascular complications. Thus,
the question of what complications are associated with early
mortality after HSCT in patients with signiﬁcant endothelial
damage may be a subject for future research.
Previous studies of VEGF-A have demonstrated contro-
versial results regarding the association between VEGF-A
level and acute GVHD. Lunn et al. [18] reported higher
VEGF-A levels in patients with acute GVHD; in contrast, Min
et al. [17] found that low VEGF-A levels on days þ7 to þ14
after HSCT was a risk factor for severe acute GVHD. This was
conﬁrmed in a laboratory mouse model in which blockage of
VEGF-A resulted in an increased rate of GVHD [39]. In the
study of Luft et al. [37], as well as the present study, no
association between VEGF-A level and GVHD was found.
These discrepancies in the literature may be explained by
different study designs, sample collection at different time
points surrounding HSCT, and the use of plasma or serum for
analysis. Thus, selection of representative time points for
VEGFmeasurement is crucial for further research in this ﬁeld.
The results of the present study regarding VOD conﬁrm
the presence of extensive endothelial cell injury during the
course of this HSCT complication [40-42]. The research
protocol included 1 additional blood collection point on the
day of VOD diagnosis. This time point was compared with
VEGF levels on day 0 and the day of engraftment in patients
who did not develop VOD. This applies to some limitations of
our study, because the assaywas performed on different days
after HSCT in the patients with VOD, but, as reported previ-
ously, peaks of endothelial damage are observed on the day
0 and on engraftment [43], justifying the use of day 0 and day
of engraftment time points in non-VOD patients for
comparison. Preclinical research has linked high circulating
VEGF-A concentrations with capillary leak and lung edema
[20,21]; thus, we had a preliminary hypothesis that capillary
leak in severe VOD might be related, at least in part, to
elevated VEGF levels. Although signiﬁcantly elevated VEGF
levels were detected in the patients with VOD, concentra-
tions up to 10-fold higher were observed in patients with
tumor-associated preconditioning VEGF elevation with no
clinical evidence of capillary leak syndrome. Thus, it is more
likely that other cytokines, such as TNF-a and IL-2, are
involved in the pathogenesis of severe VOD [44-46].
In conclusion, VEGF-A is an informative endothelial
marker that can be used to predict NRM and VOD after HSCT.
It also plays an important role in the progression of hema-
tologic malignancies and may be a promising target for
future therapies. Numerous anti-VEGF experimental agents
for treating hematologic tumors are currently under evalu-
ation [47,48], but these should be used with caution in thesetting of HSCT owing to the possible protective effects of
VEGF against early post-transplantation complications.ACKNOWLEDGMENTS
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